The Washington Post published a feature on October 13, 2026, recounting adverse experiences reported by people who used unapproved peptides including BPC-157, TB-500, and MOTS-c. The article adds named, verifiable patient voices to a public record that already includes regulatory debate over whether compounding pharmacies should be permitted to sell such substances.
The report comes roughly six weeks after the FDA’s Pharmacy Compounding Advisory Committee (PCAC) held July 2026 advisory votes recommending that six experimental peptides be added to the 503A Bulks List, a designation that affects what traditional compounding pharmacies may prepare. According to the Washington Post, FDA career scientists opposed those recommendations, citing insufficient evidence of efficacy and potential liver risks. HHS has maintained that the process satisfies ethics requirements.
The feature arrives at a sensitive moment in peptide policy. The Trump administration’s reported stopgap plan to allow temporary peptide sales remains under consideration, and the patient accounts published by the Washington Post could influence how regulators, courts, and the public weigh the risks of expanding compounding access. The report’s timing—roughly six weeks after the PCAC votes—places these accounts squarely within an active policy debate.
What happened
The Washington Post feature describes adverse experiences from individuals who used unapproved peptides including BPC-157, TB-500, and MOTS-c. The article links these accounts to the July 2026 PCAC advisory votes, in which the committee recommended that six experimental peptides be added to the 503A Bulks List. That list governs which bulk drug substances traditional compounding pharmacies may use to prepare compounded medications for individual patients.
According to the report, FDA career scientists opposed the recommendations, pointing to insufficient efficacy evidence and potential liver risks. HHS has stated that the process satisfies ethics requirements. The Washington Post article provides named patient voices that enter the public record alongside the ongoing regulatory debate, offering accounts of adverse experiences reported by people who used unregulated peptides.
Why it matters
The article amplifies documented patient-harm evidence in the public record at a sensitive moment when the Trump administration’s reported stopgap plan to allow temporary peptide sales remains under consideration. Named patient voices could inform how regulators, courts, and the public weigh the risks of expanding compounding access, particularly as the PCAC’s July 2026 recommendations remain under review by HHS and FDA.
Affected groups include peptide consumers, compounding pharmacies, FDA and HHS policymakers, and supporters of the MAHA movement. The report also highlights the divide between PCAC advisory recommendations and the concerns raised by FDA career scientists about efficacy and safety, a tension that may shape future regulatory decisions and public discourse around peptide compounding.
What to watch next
- Whether the FDA acts on the PCAC’s July 2026 advisory recommendations regarding the 503A Bulks List.
- How the Trump administration’s reported stopgap plan for temporary peptide sales proceeds.
- Whether additional patient-harm accounts or regulatory findings emerge in related proceedings.
- How HHS and FDA leadership respond to the divide between PCAC advisory recommendations and career scientists’ concerns.
- How courts, regulators, and lawmakers respond to the patient-harm evidence now in the public record.
Sources
Industry information only. Not medical or legal advice.
